Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros Therapeutics submits MAA for enclomiphene

Sep. 13, 2016

FDA names cinacalcet an orphan treatment for hyperparathyroidism in children with CKD

Sep. 12, 2016

Pivotal phase III in Tandem1 study meets primary endpoint

Sep. 12, 2016

Data on long-term administration of rhGUS in mucopolysaccharidosis type VII reported

Sep. 9, 2016

Alnylam Pharmaceuticals provides interim phase I data for ALN-AS1 in acute intermittent porphyria

Sep. 9, 2016

Repros Therapeutics reports phase II findings for oral Proellex in endometriosis

Sep. 8, 2016

La Jolla reports phase I results for LJPC-401, outlines pivotal study plans

Sep. 8, 2016

Futura reports promising topline results from pivotal study of MED-2002 for erectile dysfunction

Sep. 7, 2016

FDA clears IND for phase I trial of Trappsol Cyclo

Sep. 7, 2016

Arrowhead Pharmaceuticals begins phase II study of ARC-AAT

Sep. 7, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...